During the past decade, Charlotte Heart Group Research Center conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 9 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Charlotte Heart Group Research Center" #1 sponsor was "Boston Scientific Corporation" with 3 trials, followed by "Otsuka Pharmaceutical Development & Commercialization, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Saint Luke's Health System" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charlotte Heart Group Research Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Boston VA Research Institute, Inc." with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Cardiokine Biopharma, LLC" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Charlotte Heart Group Research Center" are "Cardiovascular Disease" (3 trials), "Congestive Heart Failure" (3 trials), "Myocardial Infarction" (3 trials), "Coronary Artery Disease" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "Charlotte Heart Group Research Center" in a lesser frequency.

Most popular intervention types in "Charlotte Heart Group Research Center" are "Drug" (13 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Dapagliflozin matching placebo" (2 trials), "Tolvaptan" (2 trials), "bococizumab (PF-04950615)" (2 trials) and "Arm 1 (ATP+Shock)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Charlotte Heart Group Research Center" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Charlotte Heart Group Research Center". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Charlotte Heart Group Research Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Charlotte Heart Group Research Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".